TIPS or Anticoagulation in Portal Vein Thrombosis

• Status: Withdrawn
• Trial end date: 2021-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing anticoagulation, which is the currently most frequently used treatment, alone, versus transjugular intrahepatic portosystemic shunt (TIPS) combined with anticoagulation, in patients presenting with recent obstructive portal vein thrombosis (ROPVT). The rationale of this study is to significantly increase the proportion of patients that achieve a complete or partial recanalization of the portal vein. The intervention of this study consists in TIPS deployment and catheter based clot removal in addition to anticoagulation. The investigators retain that this intervention will increase the proportion of patients with an open portal vein from 38% with anticoagulation alone to 83% with anticoagulation and TIPS after 6 months. Both anticoagulant therapy and clot removal/TIPS are treatments that are currently available and accepted indications for the treatment of ROPVT. Anticoagulation will be performed with unfractioned heparin or low molecular weight heparin initially and with vitamin K antagonists in the long term. The investigators plan to collect blood for biobanking at the time of inclusion and after 6 months. Blood samples for a biobank will be collected.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Treatments: Heparin

Criteria

Inclusion Criteria:

1. Recent complete thrombosis of the extrahepatic portal vein either with or without the involvement of intrahepatic branches and with or without involvement of splenic vein and superior mesenteric vein

2. Written informed consent

Exclusion Criteria:

1. Malignant Portal Vein thrombosis (neoplastic invasion)

2. Intraabdominal malignancy

3. Chronic diseases limiting life expectancy in the short term (6 months)

4. Liver transplantation

5. Unwillingness to participate

6. Contraindications to TIPS (including past or present hepatic encephalopathy Grade ≥2)

7. Child-Pugh-Turcotte score 11 or more points in patients with advanced chronic liver disease-